Cart
sales@molnova.com
GLP-1R modulator C16
CAS No. 875005-43-9
GLP-1R modulator C16( —— )
Catalog No. M35241 CAS No. 875005-43-9
GLP-1R modulator C16 is a variable modulator that significantly increases the binding affinity of GLP-4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 138 | In Stock |
|
| 5MG | 227 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGLP-1R modulator C16
-
NoteResearch use only, not for human use.
-
Brief DescriptionGLP-1R modulator C16 is a variable modulator that significantly increases the binding affinity of GLP-4.
-
DescriptionGLP-1R modulator C16 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 8.43 ± 3.82 μM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number875005-43-9
-
Formula Weight408.89
-
Molecular FormulaC21H26ClFN2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (122.28 mM; Ultrasonic (<60°C)
-
SMILESCOc1cc(CNCCN2CCOCC2)ccc1OCc1c(F)cccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
GLP-1R Agonist DMB
GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).
-
HAEGTFTSD
HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
-
des-His1-[Glu9]-Gluc...
Glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes); displays no agonist activity. Enhances glucose-stimulated pancreatic insulin release in vitro. Blocks added glucagon-induced hyperglycemia in normal rabbits without affecting glycogenolysis in vivo. Also blocks endogenous glucagon-induced hyperglycemia in streptozocin diabetic rats.
